Stay updated with breaking news from Sciences Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SELLAS Life Sciences Group, Inc. announced topline data from the Phase 2a study of SLS009 and provides an update on Phase 3 REGAL Study of GPS in AML. The REGAL Steering Committee met on March 22,...
- Phase 3 REGAL Study of GPS in AML: Enrollment Completed; Steering Committee Guided Interim Analysis Imminent; IDMC Now Scheduled in Late April-
- Phase 3 REGAL Study of GPS in AML: Enrollment Completed; Steering Committee Guided Interim Analysis Imminent; IDMC Now Scheduled in Late April - - Phase...
NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) was the recipient of a large decrease in short interest in January. As of January 31st, there was short interest totalling 3,120,000 shares, a decrease of 19.6% from the January 15th total of 3,880,000 shares. Based on an average daily trading volume, of 990,800 shares, […]